{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kondili LA"],"funding":["Research Project PITER2010"],"pagination":["1814-1825"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5765396"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["66(6)"],"pubmed_abstract":["We evaluated the cost-effectiveness of two alternative direct-acting antiviral (DAA) treatment policies in a real-life cohort of hepatitis C virus-infected patients: policy 1, \"universal,\" treat all patients, regardless of fibrosis stage; policy 2, treat only \"prioritized\" patients, delay treatment of the remaining patients until reaching stage F3. A liver disease progression Markov model, which used a lifetime horizon and health care system perspective, was applied to the PITER cohort (representative of Italian hepatitis C virus-infected patients in care). Specifically, 8,125 patients naive to DAA treatment, without clinical, sociodemographic, or insurance restrictions, were used to evaluate the policies' cost-effectiveness. The patients' age and fibrosis stage, assumed DAA treatment cost"],"journal":["Hepatology (Baltimore, Md.)"],"pubmed_title":["Modeling cost-effectiveness and health gains of a \"universal\" versus \"prioritized\" hepatitis C virus treatment policy in a real-life cohort."],"pmcid":["PMC5765396"],"funding_grant_id":["RF-2010-2315839"],"pubmed_authors":["Russo FP","Foti G","Kondili LA","Coppola C","Ciancio A","Rumi MG","Nardone G","Vinci M","Montalto G","Ferrari C","Erne EM","Ruggeri M","Zuin M","Craxi A","Santantonio TA","Andreone P","Persico M","Rolli FR","Chemello L","Alberti A","Verucchi G","Madonia S","Romano F","Rosato S","Taliani G","Borgia G","Puoti M","Quaranta MG","Di Leo A","Massari M","Blanc P","Vella S","Zignego AL","Gasbarrini A","PITER Collaborating Group","Chessa L","Cicchetti A","Raimondo G","Villa E","Ieluzzi D","Gaeta GB","Brunetto MR"],"additional_accession":[]},"is_claimable":false,"name":"Modeling cost-effectiveness and health gains of a \"universal\" versus \"prioritized\" hepatitis C virus treatment policy in a real-life cohort.","description":"We evaluated the cost-effectiveness of two alternative direct-acting antiviral (DAA) treatment policies in a real-life cohort of hepatitis C virus-infected patients: policy 1, \"universal,\" treat all patients, regardless of fibrosis stage; policy 2, treat only \"prioritized\" patients, delay treatment of the remaining patients until reaching stage F3. A liver disease progression Markov model, which used a lifetime horizon and health care system perspective, was applied to the PITER cohort (representative of Italian hepatitis C virus-infected patients in care). Specifically, 8,125 patients naive to DAA treatment, without clinical, sociodemographic, or insurance restrictions, were used to evaluate the policies' cost-effectiveness. The patients' age and fibrosis stage, assumed DAA treatment cost","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 Dec","modification":"2025-04-04T11:30:39.855Z","creation":"2019-03-27T00:14:54Z"},"accession":"S-EPMC5765396","cross_references":{"pubmed":["28741307"],"doi":["10.1002/hep.29399"]}}